Evidence map›Paper›PMID 28091532›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2017

Development of the Neuroimmune Modulator Ibudilast for the Treatment of Alcoholism: A Randomized, Placebo-Controlled, Human Laboratory Trial.

Lara A Ray, Spencer Bujarski, Steve Shoptaw, Daniel Jo Roche, Keith Heinzerling, Karen Miotto

Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03489850 (Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder), which is not on this map. Cited by 80 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed, 3 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03489850 phase2completednot on this mapstarted 2018, after this paper: background citation

Withdrawal-Related Dysphoria as a Moderator of Ibudilast for Alcohol Use Disorder

TypeinterventionalSponsorUniversity of California, Los AngelesRan2018 to 2020Enrolled52ConditionsAlcohol Use DisorderArmsIbudilast, Placebo
3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 3 syntheses or guidelines pooled it, 118 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Review
  17. Article
  18. Review
  19. Who is alcohol cue-reactive? A machine learning approach.Alcohol and alcoholism (Oxford, Oxfordshire) · 2025
    Article
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Lara A RayDepartment of Psychology, University of California, Los Angeles, CA, USA.
Spencer BujarskiDepartment of Psychology, University of California, Los Angeles, CA, USA.
Steve ShoptawDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Daniel Jo RocheDepartment of Psychology, University of California, Los Angeles, CA, USA.
Keith HeinzerlingDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Karen MiottoDepartment of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, CA, USA.
Neurobehavioral Systems · USUniversity of California, Los Angeles · US

Funding

UCLA Clinical and Translational Science InstituteUL1TR000124 · NCATS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2012 to 2015
$57.0M
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTEUL1RR033176 · NCRR · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI DUBINETT, STEVEN M. · 2011 to 2011
$15.5M
Development of Ibudilast as a Novel Treatment for AlcoholismR21AA022214 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI RAY, LARA A. · 2013 to 2014
$399k
Subjective Response and Self-Administration of Alcohol in the Human LabF31AA022569 · NIAAA · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BUJARSKI, SPENCER · 2014 to 2015
$69k
NCATS NIH HHS UL1 TR000124NCRR NIH HHS UL1 RR033176NIAAA NIH HHS F31 AA022569NIAAA NIH HHS R21 AA022214
6 · The paper itself

Abstract

Current directions in medication development for alcohol use disorder (AUD) emphasize the need to identify novel molecular targets and efficiently screen new compounds aimed at those targets. Ibudilast (IBUD) is a neuroimmune modulator that inhibits phosphodiesterase-4 and -10 and macrophage migration inhibitory factor and was recently found to reduce alcohol intake in rats by ∼50%. To advance medication development for AUD, the present study consists of a randomized, crossover, double-blind, placebo-controlled laboratory study of IBUD in nontreatment-seeking individuals with current (ie, past month) mild-to-severe AUD. This study tested the safety, tolerability, and initial human laboratory efficacy of IBUD (50 mg b.i.d.) on primary measures of subjective response to alcohol as well as secondary measures of cue- and stress-induced changes in craving and mood. Participants (N=24) completed two separate 7-day intensive outpatient protocols that included daily visits for medication administration and testing. Upon reaching a stable target dose of IBUD (or matched placebo), participants completed a stress-exposure session (day 5; PM), an alcohol cue-exposure session (day 6; AM), and an i.v. alcohol administration session (day 6; PM). Participants stayed overnight after the alcohol administration, and discharge occurred on day 7 of the protocol. Medication conditions were separated by a washout period that was ⩾7 days. IBUD was well tolerated; however, there were no medication effects on primary measures of subjective response to alcohol. IBUD was associated with mood improvements on the secondary measures of stress exposure and alcohol cue exposure, as well as reductions in tonic levels of craving. Exploratory analyses revealed that among individuals with higher depressive symptomatology, IBUD attenuated the stimulant and mood-altering effects of alcohol as compared with placebo. Together, these findings extend preclinical demonstrations of the potential utility of IBUD for the treatment of AUD and suggest that depressive symptomatology should be considered as a potential moderator of efficacy for pharmacotherapies with neuroimmune effects, such as IBUD.

Indexed as

AdultAffectAlcohol DeterrentsAlcoholismCentral Nervous System DepressantsCravingCross-Over StudiesDepressionDouble-Blind MethodEthanolFemaleHumansIndolizinesMalePyrazolesPyridinesAlcohol DeterrentsCentral Nervous System DepressantsEthanolibudilastIndolizinesPyrazolesPyridines

Identifiers

PMID28091532
PMCPMC5520778
OpenAlexW2573993882

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.